Table 2.

Analysis of dose response relationships.

Treatment group	Session	ΔSUV (95% CI)†	SUV0 (95% CI)
RT	Pre-Therapy	0.84 (0.57, 1.11)	0.46 (0.42,0.51)
	Mid-Therapy	0.75 (0.49,1.00)	0.59 (0.54,0.63)‡
	Post-Therapy	0.51 (0.10, 0.91)	0.59 (0.52,0.66)‡
RT + erlotinib	Pre-Therapy	0.57 (0.34,0.81)	0.53 (0.49,0.57)
	Mid-Therapy	0.38 (0.17,0.59)	0.58 (0.54,0.62)
	Post-Therapy	0.56 (0.30,0.82)	0.84 (0.79,0.87)‡

Population-based dose-response analysis for RT and RT+erlotinib groups at different PET sessions. Numbers given are the ΔSUV (change in SUV per percentage dose increase) and SUV₀ (SUV in un-irradiated lung), with corresponding 95% confidence intervals (CIs). ^†Multiplied by a factor 100. ^‡Significantly different from finding at pre-therapy.